Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients

Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

V. Joly, M. Moroni, E. Concia, A. Lazzarin, B. Hirschel, J. Jost, F. Chiodo, Z. Bentwich, W. C. Love, D. A. Hawkins, E. G L Wilkins, A. J. Gatell, N. Vetter, C. Greenwald, W. W. Freimuth, W. De Cian, D. Cooper, J. Hoy, D. Shaw, A. Street & 57 others E. Tschachler, N. Vetter, N. Clumeck, J. Demonty, B. Vandercam, L. Mathiesen, G. Sheehan, E. Auvergnat, G. Bouvet, G. Delzant, V. Joly, J. Kisterman, Lafeuillade, J. Lang, G. Lepeu, P. Massip, F. Raffi, K. Arasteh, H. Busch, M. Hartman, H. Jablonowski, H. Jaeger, A. Mutz, H. Rasokat, J. Rockstroh, B. Ruf, I. Schedel, W. Stille, D. Bánhegyi, Z. Bentwitch, I. Yust, F. Chiada, E. Concia, A. Lazzarin, M. Moroni, M. Piazza, M. Soranzo, J. Borleffs, G. Schrey, C. Tannapel, A. Horban, A. Sonnerborg, B. Clotet, A. Gatell, J. Lahoz, M. Leal, B. Hirschel, J. Jost, I. Ahmed-Jushuf, C. Bradbeer, R. Brettle, D. Hawkins, W. Love, A. Pozniak, K. Radcliffe, S. Tchamouroff, E. Wilkins

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Original languageEnglish
Pages (from-to)3155-3157
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume44
Issue number11
DOIs
Publication statusPublished - 2000

Fingerprint

Delavirdine
Zidovudine
HIV-1
Mutation
Reverse Transcriptase Inhibitors
Antiviral Agents
Therapeutics
Placebos

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients : Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. / Joly, V.; Moroni, M.; Concia, E.; Lazzarin, A.; Hirschel, B.; Jost, J.; Chiodo, F.; Bentwich, Z.; Love, W. C.; Hawkins, D. A.; Wilkins, E. G L; Gatell, A. J.; Vetter, N.; Greenwald, C.; Freimuth, W. W.; De Cian, W.; Cooper, D.; Hoy, J.; Shaw, D.; Street, A.; Tschachler, E.; Vetter, N.; Clumeck, N.; Demonty, J.; Vandercam, B.; Mathiesen, L.; Sheehan, G.; Auvergnat, E.; Bouvet, G.; Delzant, G.; Joly, V.; Kisterman, J.; Lafeuillade; Lang, J.; Lepeu, G.; Massip, P.; Raffi, F.; Arasteh, K.; Busch, H.; Hartman, M.; Jablonowski, H.; Jaeger, H.; Mutz, A.; Rasokat, H.; Rockstroh, J.; Ruf, B.; Schedel, I.; Stille, W.; Bánhegyi, D.; Bentwitch, Z.; Yust, I.; Chiada, F.; Concia, E.; Lazzarin, A.; Moroni, M.; Piazza, M.; Soranzo, M.; Borleffs, J.; Schrey, G.; Tannapel, C.; Horban, A.; Sonnerborg, A.; Clotet, B.; Gatell, A.; Lahoz, J.; Leal, M.; Hirschel, B.; Jost, J.; Ahmed-Jushuf, I.; Bradbeer, C.; Brettle, R.; Hawkins, D.; Love, W.; Pozniak, A.; Radcliffe, K.; Tchamouroff, S.; Wilkins, E.

In: Antimicrobial Agents and Chemotherapy, Vol. 44, No. 11, 2000, p. 3155-3157.

Research output: Contribution to journalArticle

Joly, V, Moroni, M, Concia, E, Lazzarin, A, Hirschel, B, Jost, J, Chiodo, F, Bentwich, Z, Love, WC, Hawkins, DA, Wilkins, EGL, Gatell, AJ, Vetter, N, Greenwald, C, Freimuth, WW, De Cian, W, Cooper, D, Hoy, J, Shaw, D, Street, A, Tschachler, E, Vetter, N, Clumeck, N, Demonty, J, Vandercam, B, Mathiesen, L, Sheehan, G, Auvergnat, E, Bouvet, G, Delzant, G, Joly, V, Kisterman, J, Lafeuillade, Lang, J, Lepeu, G, Massip, P, Raffi, F, Arasteh, K, Busch, H, Hartman, M, Jablonowski, H, Jaeger, H, Mutz, A, Rasokat, H, Rockstroh, J, Ruf, B, Schedel, I, Stille, W, Bánhegyi, D, Bentwitch, Z, Yust, I, Chiada, F, Concia, E, Lazzarin, A, Moroni, M, Piazza, M, Soranzo, M, Borleffs, J, Schrey, G, Tannapel, C, Horban, A, Sonnerborg, A, Clotet, B, Gatell, A, Lahoz, J, Leal, M, Hirschel, B, Jost, J, Ahmed-Jushuf, I, Bradbeer, C, Brettle, R, Hawkins, D, Love, W, Pozniak, A, Radcliffe, K, Tchamouroff, S & Wilkins, E 2000, 'Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial', Antimicrobial Agents and Chemotherapy, vol. 44, no. 11, pp. 3155-3157. https://doi.org/10.1128/AAC.44.11.3155-3157.2000
Joly, V. ; Moroni, M. ; Concia, E. ; Lazzarin, A. ; Hirschel, B. ; Jost, J. ; Chiodo, F. ; Bentwich, Z. ; Love, W. C. ; Hawkins, D. A. ; Wilkins, E. G L ; Gatell, A. J. ; Vetter, N. ; Greenwald, C. ; Freimuth, W. W. ; De Cian, W. ; Cooper, D. ; Hoy, J. ; Shaw, D. ; Street, A. ; Tschachler, E. ; Vetter, N. ; Clumeck, N. ; Demonty, J. ; Vandercam, B. ; Mathiesen, L. ; Sheehan, G. ; Auvergnat, E. ; Bouvet, G. ; Delzant, G. ; Joly, V. ; Kisterman, J. ; Lafeuillade ; Lang, J. ; Lepeu, G. ; Massip, P. ; Raffi, F. ; Arasteh, K. ; Busch, H. ; Hartman, M. ; Jablonowski, H. ; Jaeger, H. ; Mutz, A. ; Rasokat, H. ; Rockstroh, J. ; Ruf, B. ; Schedel, I. ; Stille, W. ; Bánhegyi, D. ; Bentwitch, Z. ; Yust, I. ; Chiada, F. ; Concia, E. ; Lazzarin, A. ; Moroni, M. ; Piazza, M. ; Soranzo, M. ; Borleffs, J. ; Schrey, G. ; Tannapel, C. ; Horban, A. ; Sonnerborg, A. ; Clotet, B. ; Gatell, A. ; Lahoz, J. ; Leal, M. ; Hirschel, B. ; Jost, J. ; Ahmed-Jushuf, I. ; Bradbeer, C. ; Brettle, R. ; Hawkins, D. ; Love, W. ; Pozniak, A. ; Radcliffe, K. ; Tchamouroff, S. ; Wilkins, E. / Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients : Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. In: Antimicrobial Agents and Chemotherapy. 2000 ; Vol. 44, No. 11. pp. 3155-3157.
@article{7ead18b4e317462e89f0b38ca148d5e6,
title = "Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial",
abstract = "We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90{\%} of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85{\%} of the patients.",
author = "V. Joly and M. Moroni and E. Concia and A. Lazzarin and B. Hirschel and J. Jost and F. Chiodo and Z. Bentwich and Love, {W. C.} and Hawkins, {D. A.} and Wilkins, {E. G L} and Gatell, {A. J.} and N. Vetter and C. Greenwald and Freimuth, {W. W.} and {De Cian}, W. and D. Cooper and J. Hoy and D. Shaw and A. Street and E. Tschachler and N. Vetter and N. Clumeck and J. Demonty and B. Vandercam and L. Mathiesen and G. Sheehan and E. Auvergnat and G. Bouvet and G. Delzant and V. Joly and J. Kisterman and Lafeuillade and J. Lang and G. Lepeu and P. Massip and F. Raffi and K. Arasteh and H. Busch and M. Hartman and H. Jablonowski and H. Jaeger and A. Mutz and H. Rasokat and J. Rockstroh and B. Ruf and I. Schedel and W. Stille and D. B{\'a}nhegyi and Z. Bentwitch and I. Yust and F. Chiada and E. Concia and A. Lazzarin and M. Moroni and M. Piazza and M. Soranzo and J. Borleffs and G. Schrey and C. Tannapel and A. Horban and A. Sonnerborg and B. Clotet and A. Gatell and J. Lahoz and M. Leal and B. Hirschel and J. Jost and I. Ahmed-Jushuf and C. Bradbeer and R. Brettle and D. Hawkins and W. Love and A. Pozniak and K. Radcliffe and S. Tchamouroff and E. Wilkins",
year = "2000",
doi = "10.1128/AAC.44.11.3155-3157.2000",
language = "English",
volume = "44",
pages = "3155--3157",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients

T2 - Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

AU - Joly, V.

AU - Moroni, M.

AU - Concia, E.

AU - Lazzarin, A.

AU - Hirschel, B.

AU - Jost, J.

AU - Chiodo, F.

AU - Bentwich, Z.

AU - Love, W. C.

AU - Hawkins, D. A.

AU - Wilkins, E. G L

AU - Gatell, A. J.

AU - Vetter, N.

AU - Greenwald, C.

AU - Freimuth, W. W.

AU - De Cian, W.

AU - Cooper, D.

AU - Hoy, J.

AU - Shaw, D.

AU - Street, A.

AU - Tschachler, E.

AU - Vetter, N.

AU - Clumeck, N.

AU - Demonty, J.

AU - Vandercam, B.

AU - Mathiesen, L.

AU - Sheehan, G.

AU - Auvergnat, E.

AU - Bouvet, G.

AU - Delzant, G.

AU - Joly, V.

AU - Kisterman, J.

AU - Lafeuillade,

AU - Lang, J.

AU - Lepeu, G.

AU - Massip, P.

AU - Raffi, F.

AU - Arasteh, K.

AU - Busch, H.

AU - Hartman, M.

AU - Jablonowski, H.

AU - Jaeger, H.

AU - Mutz, A.

AU - Rasokat, H.

AU - Rockstroh, J.

AU - Ruf, B.

AU - Schedel, I.

AU - Stille, W.

AU - Bánhegyi, D.

AU - Bentwitch, Z.

AU - Yust, I.

AU - Chiada, F.

AU - Concia, E.

AU - Lazzarin, A.

AU - Moroni, M.

AU - Piazza, M.

AU - Soranzo, M.

AU - Borleffs, J.

AU - Schrey, G.

AU - Tannapel, C.

AU - Horban, A.

AU - Sonnerborg, A.

AU - Clotet, B.

AU - Gatell, A.

AU - Lahoz, J.

AU - Leal, M.

AU - Hirschel, B.

AU - Jost, J.

AU - Ahmed-Jushuf, I.

AU - Bradbeer, C.

AU - Brettle, R.

AU - Hawkins, D.

AU - Love, W.

AU - Pozniak, A.

AU - Radcliffe, K.

AU - Tchamouroff, S.

AU - Wilkins, E.

PY - 2000

Y1 - 2000

N2 - We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

AB - We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

UR - http://www.scopus.com/inward/record.url?scp=0033752416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033752416&partnerID=8YFLogxK

U2 - 10.1128/AAC.44.11.3155-3157.2000

DO - 10.1128/AAC.44.11.3155-3157.2000

M3 - Article

VL - 44

SP - 3155

EP - 3157

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -